Skip to main content

Mark Denison Archives

VUMC researchers involved in developing Moderna’s COVID-19 vaccine featured in Smithsonian exhibit

Nov. 23, 2021—Researchers at Vanderbilt University Medical Center who contributed to the development of Moderna’s COVID-19 vaccine are featured in a new exhibit at the Smithsonian Institution in Washington, D.C.

Read more


Six from VUMC among most highly cited researchers

Nov. 18, 2021—Six Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

Read more


VUMC research contributed to first COVID-19 pill now under review

Oct. 1, 2021—Vanderbilt research helped allow pharmaceutical giant Merck & Co. to authorization for the first oral antiviral pill to treat COVID-19.

Read more


COVID treatment studied by VUMC gains FDA approval

Oct. 26, 2020—Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.

Read more


VUMC studies provide key positive results for COVID-19 vaccine in early-stage clinical trial

Jul. 14, 2020—An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.

Read more


New study supports remdesivir as COVID-19 treatment

Jul. 9, 2020—This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.

Read more


Medical Scientist Training Program adapts to COVID-19 challenges

Apr. 16, 2020—The Medical Scientist Training Program has been intentional in approaching the challenges presented by COVID-19.

Read more


VUMC team aids development of potential antiviral drug for COVID-19

Apr. 6, 2020—Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.

Read more


Denison named director of Pediatric Infectious Diseases

Jul. 18, 2019—Mark Denison, MD, has been named director of the Division of Pediatric Infectious Diseases in the Vanderbilt Department of Pediatrics.

Read more


Team investigates antiviral that inhibits SARS, MERS

Jun. 29, 2017—A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine.

Read more


Medical societies honor four VUMC physicians

May. 12, 2016—Four physicians from Vanderbilt University Medical Center (VUMC) have been elected to membership in two of the nation’s oldest and most respected medical honor societies — the Association of American Physicians (AAP) and the American Society for Clinical Investigation (ASCI).

Read more


Pediatrics awarded physician-scientist training support

Feb. 18, 2016—The National Institutes of Health (NIH) has awarded Vanderbilt’s Department of Pediatrics a K12 training grant to support early career faculty to become physician-scientists, the first time the department has received such an award.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more